Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

"There are many reasons an insider will sell

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
changes_iv Member Profile
Followed By 22
Posts 1,028
Boards Moderated 0
Alias Born 07/10/13
160x600 placeholder
NanoViricides reports strong pre-clinical data for COVID-19 drugs Seeking Alpha - 3/9/2021 11:26:50 AM
NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in ....Cont InvestorsHub NewsWire - 3/9/2021 9:30:00 AM
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical InvestorsHub NewsWire - 3/2/2021 7:00:08 AM
NanoViricides shares rally 29% on effectiveness of COVID-19 drug candidates in cell culture studies Seeking Alpha - 3/2/2021 6:43:58 AM
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug ....cont InvestorsHub NewsWire - 2/17/2021 7:00:00 AM
NanoViricides reports FQ2 results Seeking Alpha - 2/17/2021 6:28:57 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/16/2021 4:40:48 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 9:48:43 AM
NanoViricides’s anti-coronavirus candidate was well tolerated in animal studies Seeking Alpha - 2/8/2021 6:46:46 AM
NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP..C... InvestorsHub NewsWire - 2/8/2021 6:36:27 AM
Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants InvestorsHub NewsWire - 1/27/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/26/2021 11:05:24 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/4/2021 11:45:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/10/2020 4:31:33 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/3/2020 4:31:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2020 4:53:44 PM
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA InvestorsHub NewsWire - 11/19/2020 6:47:01 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2020 4:33:46 PM
NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19 InvestorsHub NewsWire - 11/11/2020 7:14:53 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/26/2020 4:25:50 PM
Annual Report (10-k) Edgar (US Regulatory) - 10/13/2020 5:23:45 PM
NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 InvestorsHub NewsWire - 9/16/2020 7:17:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/3/2020 5:20:21 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/31/2020 5:30:54 PM
NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 InvestorsHub NewsWire - 7/21/2020 9:42:43 AM
changes_iv   Thursday, 08/27/15 07:47:23 AM
Re: None
Post # of 145373 
"There are many reasons an insider will sell a stock, but only one reason why insiders buy: They think the stock is undervalued and will eventually go up." ~ Peter Lynch

Keep this in mind:

1) NanoViricides, Inc. commissioned the new state-of-the-art multi-kilogram Pilot Plant in Shelton, CT, to produce FluCide(TM)/GLP, sometime in early Jan 2015
2) On Mar 31, 2015 - We are now progressing to a 1kg scale-up of FluCide, and enabling in-process control instrumentation--- CMC studies to enable further scale-up from the current multi-100g scale of production to kg-scale production. CMC stands for "Chemistry, Manufacture, and Controls," and relates to being able to make the drug substance and the drug product in a reproducible fashion, batch after batch.

-We are now making the FluCide(TM) material for Phase III in large animals!

June 1, 2015, 9:47 PM

Phase I and II of tox successfully completed
Making material for last Phase in large animals
Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
"NNVC" on the New York Stock Exchange

Who do you believe, a "Tokyo Rose"-like anonymous poster with many aliases, posting from somewhere in Washington, D.C., or New York City Wall Street, Big Pharma office, the Kremlin - Russia, Beijing - China, all trying to scare "longs" out of their wits by using their financial might to drive the nav of NNVC shares to a new low...or do you believe Dr. Milton Boniuk, an independent director/insider who is buying with great frequency and confidence?
NanoViricides Appoints Baylor Professor Dr. Milton Boniuk as an Independent Board Member

WEST HAVEN, CONNECTICUT -- May 21, 2013 -- NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has appointed Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, as an independent member of the Company’s Board of Directors.

Dr. Boniuk is an astute and highly successful businessman and entrepreneur, in addition to being an accomplished eye surgeon, educator, and administrator. Currently, he is the Caroline F. Elles Chair Professor of Ophthalmology in the Alkek Eye Center at the Baylor College of Medicine, Houston, TX. He conducts a busy clinical practice in orbital surgery, eyelid reconstruction, ocular oncology and comprehensive ophthalmology. Additionally, he plays a major role in Baylor’s resident and fellow medical doctor education programs.

Dr. Boniuk has been a long term investor and strong supporter of NanoViricides, Inc.

“Milton’s strong business acumen, integrity, and professional expertise will be of great help in strengthening our corporate governance as well as fostering our drug development activities,” said Eugene Seymour, MD, MPH, CEO of the Company.

Dr. Boniuk has made significant contributions in cataract surgery, glaucoma, corneal dystrophies, retinal diseases and surgery. He is a nationally and internationally recognized expert in the pathology and surgical management of orbital and intra-ocular tumors. His description of the ocular pathology of the congenital rubella syndrome in 1967 was a landmark publication. Of note, Dr. Boniuk has made substantial medical contributions in areas that are of great significance to the Company, such as ocular adenoviral infections, that cause epidemic kerato-conjunctivitis (EKC). The Company has developed a drug candidate for EKC infection that was successfully tested in rabbits. These animals serve as a surrogate for the viral disease in human eyes.

“Dr. Boniuk brings a unique set of skills to the Board of NanoViricides, Inc.,” said Anil R. Diwan, PhD, President of the Company, adding, “He shares our enthusiasm for the novel biomimetic nanoviricides® technologies and the resulting anti-viral drugs. In addition to strengthening our corporate governance, he will be of great value in progressing our drug development programs into the clinic.”

Dr. Boniuk is also well known for his philanthropic endeavors. He and his wife Laurie founded the National Society for Parent and Child Development in 1989. In 1994, he established the Lions Eye Bank Foundation’s Milton Boniuk, M.D., Endowment Fund to support resident research in the Ophthalmology Department at Baylor. In 2004, Milton and Laurie Boniuk contributed $5 million to Rice University to establish the Boniuk Center for the Study and Advancement of Religious Tolerance. In 2013, they gave an additional $28.5M to Rice University to upgrade this Center to The Boniuk Institute for the Study and Advancement of Religious Tolerance. The Boniuk Institute will conduct research, public outreach and educational programming. Its mission is to foster multidisciplinary research that leads to innovative ways to understand and achieve religious tolerance.

Dr. Boniuk earned his MD at the Dalhousie University, Halifax, Nova Scotia, Canada, followed by an internship at the Victoria General Hospital, Halifax, Nova Scotia, Canada, and Residency at the Center for Ophthalmology, Jefferson Medical College - Wills Eye Hospital, Philadelphia, PA. In addition, he served a Fellowship in Ophthalmic Pathology at the world-renowned Armed Forces Institute of Pathology, Washington, DC.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences